ESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC)

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F23%3A43925931" target="_blank" >RIV/00064173:_____/23:43925931 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11120/23:43925931

Výsledek na webu

<a href="https://doi.org/10.1016/j.annonc.2023.08.001" target="_blank" >https://doi.org/10.1016/j.annonc.2023.08.001</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.annonc.2023.08.001" target="_blank" >10.1016/j.annonc.2023.08.001</a>

Jazyk výsledku

angličtina

Název v původním jazyce

ESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC)

Popis výsledku v původním jazyce

The management of breast cancer during pregnancy (PrBC) is a relatively rare indication and an area where no or little evidence is available since randomized controlled trials cannot be conducted. In general, advances related to breast cancer treatment outside pregnancy cannot always be translated to PrBC, because both the interests of the mother and of the unborn should be considered. Evidence remains limited and/or conflicting in some specific areas where the optimal approach remains controversial. In 2022, the European Society for Medical Oncology (ESMO) held a virtual consensus-building process on this topic to gain insights from a multidisciplinary group of experts and develop statements on controversial topics that cannot be adequately addressed in the current evidence-based ESMO Clinical Practice Guideline. The aim of this consensus-building process was to discuss controversial issues relating to the management of patients with breast cancer during pregnancy. The virtual meeting included a multidisciplinary panel of 24 leading experts from 13 countries and was chaired by S. Loibl and F. Amant. All experts were allocated to one of four different working groups. Each working group covered a specific subject area with two chairs appointed: 1. Breast cancer during pregnancy: incidence, epidemiology, biology and pathology. Diagnostic work up, Staging and Risk assessment, prognosis (Chairs: Vincent Vandecaveye, Fedro Peccatori) 2. Clinical pharmacology of systemic agents during pregnancy. Management of localized disease and (neo) adjuvant therapies. Management of systemic disease (Chairs: Giuseppe Curigliano, Peter Schmid) 3. Obstetric care and fetal/newborn follow-up and outcomes, metastases to fetus. Management of pregnancy during anticancer therapy. Lactation. Psychological support (Chairs: Elyce Cardonick, Mathilde van Gerwen) Planning, preparation and execution of the consensus process was conducted according to the ESMO standard operating procedures.

Název v anglickém jazyce

ESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC)

Popis výsledku anglicky

The management of breast cancer during pregnancy (PrBC) is a relatively rare indication and an area where no or little evidence is available since randomized controlled trials cannot be conducted. In general, advances related to breast cancer treatment outside pregnancy cannot always be translated to PrBC, because both the interests of the mother and of the unborn should be considered. Evidence remains limited and/or conflicting in some specific areas where the optimal approach remains controversial. In 2022, the European Society for Medical Oncology (ESMO) held a virtual consensus-building process on this topic to gain insights from a multidisciplinary group of experts and develop statements on controversial topics that cannot be adequately addressed in the current evidence-based ESMO Clinical Practice Guideline. The aim of this consensus-building process was to discuss controversial issues relating to the management of patients with breast cancer during pregnancy. The virtual meeting included a multidisciplinary panel of 24 leading experts from 13 countries and was chaired by S. Loibl and F. Amant. All experts were allocated to one of four different working groups. Each working group covered a specific subject area with two chairs appointed: 1. Breast cancer during pregnancy: incidence, epidemiology, biology and pathology. Diagnostic work up, Staging and Risk assessment, prognosis (Chairs: Vincent Vandecaveye, Fedro Peccatori) 2. Clinical pharmacology of systemic agents during pregnancy. Management of localized disease and (neo) adjuvant therapies. Management of systemic disease (Chairs: Giuseppe Curigliano, Peter Schmid) 3. Obstetric care and fetal/newborn follow-up and outcomes, metastases to fetus. Management of pregnancy during anticancer therapy. Lactation. Psychological support (Chairs: Elyce Cardonick, Mathilde van Gerwen) Planning, preparation and execution of the consensus process was conducted according to the ESMO standard operating procedures.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Annals of Oncology

ISSN

0923-7534

e-ISSN

1569-8041

Svazek periodika

34

Číslo periodika v rámci svazku

10

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

18

Strana od-do

849-866

Kód UT WoS článku

001088552900001

EID výsledku v databázi Scopus

2-s2.0-85170414993